Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cytochrome P450 2C19

2

Dopamine transporter

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1998

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Narcolepsy

2

Obstructive sleep apnea

2

Sleep disorder

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Cephalon

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CHEBI

2

ChEMBL

2

DAILYMED

2

DRUG BANK

2

DRUG CENTRAL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

PSYCHOANALEPTICS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Centrally acting sympathomimetics

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

MODAFINIL

R3UK8X3U3D

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1998

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Dopamine transporter

Cytochrome P450 2C19

Dopamine transporter

Cytochrome P450 2C19

Conditions:

Obstructive sleep apnea

Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to...

the dopamine transporter and inhibit dopamine reuptake. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.

ARMODAFINIL

V63XWA605I

Export Data
Search for Structure

Status:

US Approved Rx (2012)

First approved in 1998

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine transporter

Cytochrome P450 2C19

Dopamine transporter

Cytochrome P450 2C19

Conditions:

Obstructive sleep apnea

Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to...

the dopamine transporter and inhibit dopamine reuptake. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1